Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nek2 siRNA
- Development stage
- Preclinical
- Lead developer
- Nagoya University Graduate School of Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
Nek2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of NIMA-related kinase 2 (Nek2), a member of the serine/threonine kinase family that serves as an essential mitotic regulator involved in centrosome splitting. Overexpression of Nek2 has been implicated in the progression and metastasis of various human malignancies, including pancreatic, cholangiocarcinoma, breast, and colorectal cancers. By facilitating the degradation of Nek2 mRNA through the RNA interference (RNAi) pathway, this therapeutic approach aims to inhibit tumor cell division and suppress tumorigenic growth. Preclinical studies conducted by researchers at Nagoya University have demonstrated that Nek2 siRNA can effectively reduce tumor volume and the number of liver metastases in pancreatic cancer xenograft models.
- Other names
- siNek2siNek-2siNek 2NIMA-related kinase 2 siRNA
02
Targets
NEK2 (NIMA-related kinase 2)
Beyond the preview
Go deeper on Nek2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nek2 siRNA.